BARROW NEUROLOGICAL INSTITUTE

The Ivy Brain Tumor Center at Barrow Neurological Institute is testing a new drug, Niraparib, in clinical trials to potentially extend Glioblastoma (GBM) patients' lives by a few months. Current median survival is 16 months. Early-phase trials showed a new median survival of 20 months.